Alessandro Cordiale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alessandro Cordiale has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Alessia Maria Pignataro
Laboratory of Molecular Materials, Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Campus Valla
1 shared publication - Alexander Jenssen
Laboratory of Molecular Materials, Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Campus Valla
1 shared publication - Cornelia Christina Schwarz
Laboratory of Molecular Materials, Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Campus Valla
1 shared publication - Daniel Aili
Laboratory of Molecular Materials, Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Linköping University, SE-581 83, Linköping, Sweden
1 shared publication Ehsanul Hoque Apu
Bitonte College of Dentistry, Department of Biomedical Sciences, Northeast Ohio Medical University
1 shared publication- Elena Cambria
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (44)
An innervated and vascularized HNSCC-on-a-chip model built on defined and tunable engineered extracellular matrices
Understanding the tumor microenvironment requires experimental platforms that faithfully recapitulate its key components. Here, we present an innervated and vascularized head and neck squamous cell carcinoma (HNSCC)-on-a-chip platform built with fully defined and tunable engineered extracellular matrices (eECMs). In a stepwise increase of complexity, we first cocultured patient-derived HNSCC cells, cancer-associated fibroblasts, and endothelial cells within tailored eECMs, revealing extracellular matrix-dependent differences in transcriptional state, multicellular self-organization, and chemotherapeutic sensitivity. We then integrated these three-dimensional constructs into a cancer–vasculature interface, which enabled analysis of eECM-dependent directional collective migration and invasion. Finally, we incorporated trigeminal innervation through injectable 3D human bioengineered trigeminal ganglia, establishing a chip-based innervation–tumor–vasculature tri-interface. Together, this all-human platform integrates fully defined ECM, vasculature, and innervation in a single modular system to investigate tumor organization, invasion, and therapeutic responses within a controlled human microenvironment.
- 27 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (44)
Open AccessAn innervated and vascularized HNSCC-on-a-chip model built on defined and tunable engineered extracellular matrices
Understanding the tumor microenvironment requires experimental platforms that faithfully recapitulate its key components. Here, we present an innervated and vascularized head and neck squamous cell carcinoma (HNSCC)-on-a-chip platform built with fully defined and tunable engineered extracellular matrices (eECMs). In a stepwise increase of complexity, we first cocultured patient-derived HNSCC cells, cancer-associated fibroblasts, and endothelial cells within tailored eECMs, revealing extracellular matrix-dependent differences in transcriptional state, multicellular self-organization, and chemotherapeutic sensitivity. We then integrated these three-dimensional constructs into a cancer–vasculature interface, which enabled analysis of eECM-dependent directional collective migration and invasion. Finally, we incorporated trigeminal innervation through injectable 3D human bioengineered trigeminal ganglia, establishing a chip-based innervation–tumor–vasculature tri-interface. Together, this all-human platform integrates fully defined ECM, vasculature, and innervation in a single modular system to investigate tumor organization, invasion, and therapeutic responses within a controlled human microenvironment.
- Open Access
- 7 July 2026
- Published by IOP Publishing in Biofabrication
- Vol. 18 (3) , 035033
IntravChip: a vascularized and perfused microfluidic model of the primary tumor microenvironment to collect intravasated tumor cells
Hematogenous metastasis is initiated when tumor cells (TCs) intravasate into the vasculature, yet intravasation remains poorly understood because it is difficult to observe in vivo and intravasated TCs are challenging to isolate. To address these challenges, we developed IntravChip, a continuously perfused microfluidic platform containing a vascularized primary tumor microenvironment (TME) enabling the observation of TC intravasation, and a downstream chamber to collect intravasated TCs. The IntravChip can support a high TC concentration in the TME while maintaining complete vascular perfusion, which we found was necessary to collect intravasated cells. Using MDA-MB-231 breast TCs, we identified an optimal initial TC seeding density that, by day 9, yields a densely populated TME and 100-440 collected intravasated TCs. We validated the IntravChip across several TC types, showing that MDA-MB-231 and MV3 TCs have the highest intravasation rates while MCF-7 TCs have low intravasation efficiency. We also show that the IntravChip is compatible with super-resolution nano-imaging. Our devices enabled high-quality STORM imaging, which revealed that H3K9me3 nanodomains are significantly differentially distributed in intravasated MDA-MB-231 tumor cells compared to those residing in the TME. Finally, the IntravChip was validated as a platform to test the effects of anti-cancer drugs on tumor cells and on the vasculature. We showed that a 5 μM concentration of sorafenib reduced intravasation events by 69% without impacting the morphology of the microvascular networks (MVNs), while a 10 μM concentration led to a significant decrease in vessel diameter. This platform enables quantitative analysis of TC intravasation, collection of intravasated TCs for characterization, and screening of anti-metastatic therapies.
- 7 July 2026
- Published by IOP Publishing in Biofabrication
- Vol. 18 (3) , 035033
Open AccessIntravChip: a vascularized and perfused microfluidic model of the primary tumor microenvironment to collect intravasated tumor cells
Hematogenous metastasis is initiated when tumor cells (TCs) intravasate into the vasculature, yet intravasation remains poorly understood because it is difficult to observe in vivo and intravasated TCs are challenging to isolate. To address these challenges, we developed IntravChip, a continuously perfused microfluidic platform containing a vascularized primary tumor microenvironment (TME) enabling the observation of TC intravasation, and a downstream chamber to collect intravasated TCs. The IntravChip can support a high TC concentration in the TME while maintaining complete vascular perfusion, which we found was necessary to collect intravasated cells. Using MDA-MB-231 breast TCs, we identified an optimal initial TC seeding density that, by day 9, yields a densely populated TME and 100-440 collected intravasated TCs. We validated the IntravChip across several TC types, showing that MDA-MB-231 and MV3 TCs have the highest intravasation rates while MCF-7 TCs have low intravasation efficiency. We also show that the IntravChip is compatible with super-resolution nano-imaging. Our devices enabled high-quality STORM imaging, which revealed that H3K9me3 nanodomains are significantly differentially distributed in intravasated MDA-MB-231 tumor cells compared to those residing in the TME. Finally, the IntravChip was validated as a platform to test the effects of anti-cancer drugs on tumor cells and on the vasculature. We showed that a 5 μM concentration of sorafenib reduced intravasation events by 69% without impacting the morphology of the microvascular networks (MVNs), while a 10 μM concentration led to a significant decrease in vessel diameter. This platform enables quantitative analysis of TC intravasation, collection of intravasated TCs for characterization, and screening of anti-metastatic therapies.